Published in J Cancer Res Clin Oncol on November 25, 2005
Overweight is associated with improved cancer-specific survival in patients with organ-confined renal cell carcinoma. J Cancer Res Clin Oncol (2009) 0.95
MHC class I antigen presentation and implications for developing a new generation of therapeutic vaccines. Ther Adv Vaccines (2014) 0.91
Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer? BMC Cancer (2009) 0.90
Inactivation of Lactobacillus leichmannii ribonucleotide reductase by 2',2'-difluoro-2'-deoxycytidine 5'-triphosphate: covalent modification. Biochemistry (2010) 0.89
Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma. Br J Cancer (2013) 0.87
Clinical behavior of chromophobe renal cell carcinoma is less aggressive than that of clear cell renal cell carcinoma, independent of Fuhrman grade or tumor size. Virchows Arch (2014) 0.81
Incidence and long-term prognosis of papillary renal cell carcinoma. J Cancer Res Clin Oncol (2008) 0.81
Telmisartan induces apoptosis and regulates Bcl-2 in human renal cancer cells. Exp Biol Med (Maywood) (2014) 0.80
Effects of oleic acid on cell proliferation through an integrin-linked kinase signaling pathway in 786-O renal cell carcinoma cells. Oncol Lett (2013) 0.78
Autocrine and paracrine STIP1 signaling promote osteolytic bone metastasis in renal cell carcinoma. Oncotarget (2017) 0.75
Notch signaling plays a crucial role in cancer stem-like cells maintaining stemness and mediating chemotaxis in renal cell carcinoma. J Exp Clin Cancer Res (2017) 0.75
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature (1999) 23.45
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med (2003) 14.59
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol (2000) 9.70
Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A (1994) 6.48
Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A (1996) 5.69
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood (2003) 5.07
Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med (2000) 4.99
The changing natural history of renal cell carcinoma. J Urol (2001) 4.72
Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol (2004) 4.68
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol (2004) 4.67
Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol (2003) 3.38
Temozolomide and treatment of malignant glioma. Clin Cancer Res (2000) 2.95
Systemic therapy for renal cell carcinoma. J Urol (2000) 2.89
VEGF-receptor signal transduction. Trends Biochem Sci (2003) 2.89
Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer (2001) 2.82
The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol Cell Biol (1997) 2.76
Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol (2003) 2.24
PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs (2005) 2.09
Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol (2004) 2.07
Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol (2005) 2.05
Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol (2004) 1.86
Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol (1999) 1.84
Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol (1995) 1.83
Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther (2003) 1.61
Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res (2004) 1.59
Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J Clin Oncol (2002) 1.56
Interferon alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma. J Clin Oncol (2003) 1.51
Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens. Clin Cancer Res (2004) 1.42
Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem Pharmacol (1990) 1.34
Chemotherapy for renal cell carcinoma. Semin Oncol (2000) 1.29
Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases. Cancer Res (1988) 1.28
Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol (2000) 1.26
Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. Blood (2003) 1.22
Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer (1995) 1.19
Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol (1993) 1.18
A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer (2004) 1.15
Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens. Ann Oncol (2005) 1.14
Chemotherapy for renal cell carcinoma. Anticancer Res (1999) 1.07
Interaction of fluorouracil and interferon in human colon cancer cell lines: cytotoxic and cytokinetic effects. Cancer Res (1990) 1.03
Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Français d'Immunothérape. J Clin Oncol (1999) 0.94
Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group Study. Cancer (1994) 0.94
Oxaliplatin plus 5-fluorouracil: clinical experience in patients with advanced colorectal cancer. Semin Oncol (1998) 0.90
Recent advances in kidney cancer and metastatic disease. BJU Int (2001) 0.89
Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: results of a European multi-center phase III study. Ann Oncol (1992) 0.87
Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels. Ann Oncol (2002) 0.87
Phase II trial of thalidomide in renal-cell carcinoma. Ann Oncol (2002) 0.87
Interferon inhibition of thymidine incorporation into DNA through effects on thymidine transport and uptake. J Cell Physiol (1984) 0.86
Interferon effects upon fluorouracil metabolism by HL-60 cells. Biochem Biophys Res Commun (1989) 0.86
IPM chemotherapy in cytokine refractory renal cell cancer. Br J Cancer (2003) 0.84
Biomodulation of 5-fluorouracil by interferon-alpha in human renal carcinoma cells: relationship to the expression of thymidine phosphorylase. Cancer Chemother Pharmacol (1999) 0.82
Second line therapy with low-dose subcutaneous interleukin-2 alone in advanced renal cancer patients resistant to interferon-alpha. Eur J Cancer (1992) 0.81
Subcutaneous interleukin-2, interferon alpha-2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: a phase II trial. Br J Cancer (2003) 0.80
A phase II trial of oral temozolomide in patients with metastatic renal cell cancer. Cancer Chemother Pharmacol (2002) 0.80
Phase I-II study of irinotecan in combination with mitomycin C in patients with advanced gastrointestinal cancer. Am J Clin Oncol (2001) 0.80
Capecitabine monotherapy and in combination with immunotherapy in the treatment of metastatic renal cell carcinoma. Anticancer Drugs (2003) 0.80
Activity of dolastatin 10 against small-cell lung cancer in vitro and in vivo: induction of apoptosis and bcl-2 modification. Cancer Chemother Pharmacol (1999) 0.80
Antitumor effect of irinotecan hydrochloride (CPT-11) on human renal tumors heterotransplanted in nude mice. Int J Urol (1998) 0.79
Thalidomide in the treatment of cancer. Anticancer Drugs (2000) 0.79
Nonmyeloablative stem cell transplantation in metastatic renal cell carcinoma: delayed graft-versus-tumor effect is associated with chimerism conversion but transplantation has high toxicity. Bone Marrow Transplant (2004) 0.79
Thalidomide reduces serum C-reactive protein and interleukin-6 and induces response to IL-2 in a fraction of metastatic renal cell cancer patients who failed IL-2-based therapy. Int J Cancer (2004) 0.79
Phase II study of dolastatin-10 as first-line treatment for advanced colorectal cancer. Am J Clin Oncol (2002) 0.78
Vinorelbine and interferon-alpha2c as second-line therapy in metastatic renal cell carcinoma. Anticancer Drugs (2000) 0.77
Application of retinoids in the treatment of renal cell carcinoma--a futile effort? Anticancer Drugs (2004) 0.77
Second-line therapy with interferon-alpha plus vinblastine in metastatic renal cell cancer patients progressed under interleukin-2 subcutaneous immunotherapy. Tumori (1995) 0.77
AE-941, a multifunctional antiangiogenic compound: trials in renal cell carcinoma. Expert Opin Investig Drugs (2003) 0.76
Thalidomide therapy for renal cell carcinoma. Crit Rev Oncol Hematol (2003) 0.76
A phase II trial of temozolomide and IFN-alpha in patients with advanced renal cell carcinoma. J Interferon Cytokine Res (2004) 0.76
Application of thalidomide/interleukin-2 in immunochemotherapy-refractory metastatic renal cell carcinoma. Anticancer Drugs (2005) 0.76
A phase II study of 13-cis-retinoic acid in patients with advanced renal cell carcinoma. Invest New Drugs (1997) 0.76
Oxaliplatin, 5-fluorouracil, and folinic acid (Folfox) in patients with metastatic renal cell carcinoma: results of a pilot study. Am J Clin Oncol (2000) 0.75
Clinical and in vitro response to 13-cis-retinoic acid in interferon-alpha resistant renal cell carcinoma. Cancer Biother Radiopharm (1997) 0.75
Limited efficacy of interferon-alpha and vinblastine as second line biochemotherapy regimen in patients with progressive metastatic renal cell carcinoma. Cancer Biother (1993) 0.75
Unexpected toxicity of combination thalidomide and interferon alpha-2a treatment in metastatic renal cell carcinoma. J Clin Oncol (2002) 0.75
Temozolomide in patients with high grade gliomas. Oncology (2000) 0.75
Nonmyeloablative allogeneic stem cell transplantation in metastatic renal cell carcinoma: a new therapeutic option or just a clinical experiment? World J Urol (2005) 0.75
Basic science and research in renal cell carcinoma: from workbench to bedside. Curr Opin Urol (2003) 0.75
[The major response of metastatic kidney cancer to the combination of oxaliplatin, 5-fluorouracil and folinic acid (FOX-FOL)]. Presse Med (1998) 0.75
Pyonephrosis: diagnosis and treatment. Br J Urol (1992) 1.97
Sacral colpopexy with concurrent Burch colposuspension in patients with vaginal vault prolapse. Urol Int (2006) 1.60
A star in a 15.2-year orbit around the supermassive black hole at the centre of the Milky Way. Nature (2002) 1.56
Decision support software to help primary care physicians triage skin cancer: a pilot study. Arch Dermatol (2000) 1.53
Hemodialysis reduces inhibitory effect of plasma ultrafiltrate on LDL oxidation and subsequent endothelial reactions. Kidney Int (2006) 1.46
[Second-line thalidomide/IL-2 therapy in metastatic kidney cancer--results of a pilot study]. Aktuelle Urol (2006) 1.42
[Toxicity and efficacy of intermittent docetaxel chemotherapy for hormone refractory prostate cancer]. Aktuelle Urol (2009) 1.39
Aortic valve replacement: is the stentless xenograft an alternative to the homograft? Midterm results. Ann Thorac Surg (1999) 1.38
A computer-based assessment detects regimen misunderstandings and nonadherence for patients on HIV antiretroviral therapy. AIDS Care (2002) 1.36
Kv1.3 potassium channels are localized in the immunological synapse formed between cytotoxic and target cells. Proc Natl Acad Sci U S A (2004) 1.31
Innovation in detection of microparticles and exosomes. J Thromb Haemost (2013) 1.24
Neuroradiology of cholesteatomas. AJNR Am J Neuroradiol (2010) 1.20
Giant calculus of the posterior urethra following recurrent penile urethral stricture. Urol Int (2002) 1.16
A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer (2004) 1.15
Identification of steroid sulfate transport processes in the human mammary gland. J Clin Endocrinol Metab (2003) 1.13
[Cocaine-body-packing. Infrequent indication for laparotomy]. Chirurg (2003) 1.11
A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients. World J Urol (2010) 1.08
Renal artery embolism: clinical features and therapeutic options. J Urol (1992) 1.08
[Gender-specific characteristics and survival of renal cell carcinoma]. Urologe A (2008) 1.05
Ureteroscopy without routine balloon dilation: an outcome assessment. J Urol (1992) 1.04
Radiommunological measurement of leptin in plasma of obese and diabetic human subjects. Endocrinology (1996) 1.03
K+ channel blockers: novel tools to inhibit T cell activation leading to specific immunosuppression. Curr Pharm Des (2006) 1.03
Clinical experience with a new ultrasonic and LithoClast combination for percutaneous litholapaxy. BJU Int (2002) 0.99
Magnetic resonance imaging in the diagnosis of acute injured distal tibiofibular syndesmosis. Invest Radiol (1997) 0.99
Cardiac tamponade following pericarditis 18 days after catheter ablation of atrial fibrillation. Clin Res Cardiol (2010) 0.97
Pleomorphic lobular carcinoma of the breast: its cell kinetics, expression of oncogenes and tumour suppressor genes compared with invasive ductal carcinomas and classical infiltrating lobular carcinomas. Histopathology (2001) 0.96
Influence of age on the signal transduction of T cells in mice. Int Immunol (1993) 0.96
Prognostic and predictive significance of ErbB-2 breast tumor levels measured by enzyme immunoassay. J Clin Oncol (2001) 0.95
Modulation of pro-epidermal growth factor, pro-transforming growth factor alpha and epidermal growth factor receptor gene expression in human renal carcinomas. Cancer Res (1990) 0.95
Internally concealed cocaine: analytical and diagnostic aspects. J Forensic Sci (1995) 0.95
Somatotopic mapping of the human primary somatosensory cortex by fully automated tactile stimulation using functional magnetic resonance imaging. Neurosci Lett (1999) 0.95
Signalling inhibitors against Mycobacterium tuberculosis--early days of a new therapeutic concept in tuberculosis. Curr Med Chem (2008) 0.94
Factor XIII substitution in ulcerative colitis. Lancet (1995) 0.94
Intrapleural topical application of cisplatin with the surgical carrier Vivostat increases the local drug concentration in an immune-competent rat model with malignant pleuromesothelioma. J Thorac Cardiovasc Surg (2006) 0.94
Local recurrence of an oncocytic adrenocortical carcinoma with ovary metastasis. J Urol (2001) 0.93
Quality-of-life issues in the treatment of testicular cancer. World J Urol (1999) 0.93
Endogenous myoglobin in human breast cancer is a hallmark of luminal cancer phenotype. Br J Cancer (2010) 0.93
Anion channels in chara corallina tonoplast membrane: calcium dependence and rectification. J Membr Biol (1999) 0.93
The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. J Urol (2001) 0.92
The serum paraoxonase activity in patients with chronic renal failure and hyperlipidemia. Nephron (1998) 0.92
Purulent corporeal cavernositis secondary to papaverine-induced priapism. J Urol (1991) 0.92
Chordoid glioma of the third ventricle: confirmatory report of a new entity. Hum Pathol (1999) 0.91
Effects of toxins Pi2 and Pi3 on human T lymphocyte Kv1.3 channels: the role of Glu7 and Lys24. J Membr Biol (2001) 0.90
Viscocanalostomy versus trabeculectomy for primary open angle glaucoma: 4-year prospective randomized clinical trial. Eye (Lond) (2007) 0.89
[Immunochemical studies on the problem of the "pregnancy zone". VI. Occurrence, identification, and demonstration of the pregnancy-specific protein in the pregnancy zone]. Arch Gynakol (1972) 0.89
Serum DNA and urine DNA alterations of urinary transitional cell bladder carcinoma detected by fluorescent microsatellite analysis. Int J Cancer (2001) 0.89
Pseudo-pericardial tamponade after perforation of the right coronary artery. Heart (2004) 0.88
[Immunochemical studies of the problem of the "pregnancy zone". I. Antigravida immune serum]. Arch Gynakol (1969) 0.88
[Immunochemical studies on the problem of the "pregnancy zone". VII. Radioimmunological studies on the affinity of pregnancy zone proteins to estrogens in vitro]. Arch Gynakol (1972) 0.87
CNK1 is a novel Akt interaction partner that promotes cell proliferation through the Akt-FoxO signalling axis. Oncogene (2010) 0.87
Vitamin E, lipid profile, and peroxidation in hemodialysis patients. Kidney Int Suppl (2001) 0.86
Relative advantage: a substitute for mean fitness in Fisher's fundamental theorem? J Theor Biol (1999) 0.86
Pelvic floor exercises, electrical stimulation and biofeedback after radical prostatectomy: results of a prospective randomized trial. J Urol (2003) 0.86
Immunostimulatory CpG oligonucleotides reduce tumor burden after intravesical administration in an orthotopic murine bladder cancer model. Tumour Biol (2005) 0.86
[Isolated epididymal torsion in dissociation of testis-epididymis]. Urologe A (2002) 0.86
Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional study. Breast Cancer Res Treat (2014) 0.85
Melanotic progonoma as a component of ovarian teratoma. Histopathology (2000) 0.85
[Changes in blood rheology and microcirculation after preparatory combined thrombocytapheresis and plasmapheresis]. Beitr Infusionsther Transfusionsmed (1997) 0.85
Signet-ring cell ependymoma: case report with implications for pathogenesis and differential diagnosis. Pathol Res Pract (1999) 0.85
[Inhibition of lymphocyte transformation in vitro by protein fractions from the serum of pregnant women and placental extracts]. Zentralbl Gynakol (1973) 0.85
Apoptosis is triggered by the cyclic AMP signalling pathway in renal mesangial cells. FEBS Lett (1996) 0.85
[High-dose-rate brachytherapy of prostatic carcinoma with iridium 192]. Strahlenther Onkol (1992) 0.84
Factor XIII in chronic inflammatory bowel diseases. Semin Thromb Hemost (1996) 0.84
Effect of elastin peptides on human monocytes: Ca2+ mobilization, stimulation of respiratory burst and enzyme secretion. Biochem Biophys Res Commun (1986) 0.84
Transcriptional and biochemical signatures of divergence in natural populations of two species of New Zealand alpine Pachycladon. Mol Ecol (2008) 0.84
Biochemical and serological examination of some Mycoplasma strains of goose origin. Acta Vet Hung (1984) 0.84
Efficacy and safety of inhaled recombinant interleukin-2 in high-risk renal cell cancer patients compared with systemic interleukin-2: an outcome study. Folia Biol (Praha) (2003) 0.84
MIB-1 immunoreactivity reveals different labelling in low-grade and in malignant epithelial neoplasms of the choroid plexus. Histopathology (1996) 0.84
Current status of cytotoxic chemotherapy in hormone refractory prostate cancer. Eur Urol (2001) 0.84
Ibandronate in the treatment of prostate cancer associated painful osseous metastases. Prostate Cancer Prostatic Dis (2002) 0.83
Management of contralateral adrenal metastasis from renal cell carcinoma: possibility of inferior vena cava tumour thrombus. Scand J Urol Nephrol (2000) 0.83
Melanosis arising in a lumpectomy scar, mimicking invasive carcinoma. Histopathology (1999) 0.83
Familial paracentric inversion inv(2)(q31q36). Hum Genet (1985) 0.83
Relationship of serum resistin level to traits of metabolic syndrome and serum paraoxonase 1 activity in a population with a broad range of body mass index. Exp Clin Endocrinol Diabetes (2008) 0.83
The quantitative determination of coronary flow with a positron (rubidium-84). Circulation (1965) 0.83
Identification of a new human Smad6 splice variant. Andrologia (2008) 0.83
[Immuno-chemical investigations on the problem of the "pregnancy zone". 3. Analysis of pregnancy-typical antigens]. Arch Gynakol (1970) 0.83
Purification, characterization and mechanism of action of scatter factor from human placenta. EXS (1991) 0.82
Inguinal fibrolipoma of the spermatic cord: discrepancies between clinical and histopathological findings. Urol Int (2003) 0.82
[Immunochemical investigations on the protein of the "pregnancy zone". IX. Isolation of the pregnancy zone protein by immunoadsorption (author's transl)]. Arch Gynakol (1974) 0.82
Effects of TGF-betas and a specific antagonist on apoptosis of immature rat male germ cells in vitro. Apoptosis (2006) 0.82
[The specificity of peptide-PABA-test (author's transl)]. Z Gastroenterol (1979) 0.82